PA
MBAV

PharVision Advisers’s M3-Brigade Acquisition V Corp MBAV Stock Holding History

PharVision Advisers’s Portfolio MBAV Stock Details MBAV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,238
Closed -$247K – 680
2025
Q4 		$247K Buy
+23,238
New +$247K 0.13% 400

Other funds holding MBAV

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
JG
Jain Global New York $24.2B AUM 34.82% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

PharVision Advisers's MBAV Position: Q1 2026 in Review

PharVision Advisers sold out of M3-Brigade Acquisition V Corp (MBAV) in Q1 2026, closing a stake of 23,238 shares — an estimated $247K sold.

PharVision Advisers first reported a position in MBAV in Q4 2025 and held it in 1 quarter. The position peaked at $247K in Q4 2025. 49 funds tracked by Wall St. Rank hold MBAV as of Q1 2026.

  • PharVision Advisers reported no remaining M3-Brigade Acquisition V Corp position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 23,238 M3-Brigade Acquisition V Corp shares in Q1 2026, an estimated $247K.
  • PharVision Advisers first reported a position in M3-Brigade Acquisition V Corp in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's M3-Brigade Acquisition V Corp position peaked at $247K in Q4 2025.
  • 49 funds tracked by Wall St. Rank held M3-Brigade Acquisition V Corp as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.